From 7bfdf266072af91db7c860c68722dc218fb8bafb Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 15:29:32 +0000 Subject: [PATCH] extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 +++++ ...-cardiovascular-and-metabolic-endpoints.md | 6 +++++ ...eating-largest-per-patient-cost-savings.md | 6 +++++ ...rics but only 14 percent bear full risk.md | 6 +++++ ...ensive-semaglutide-medicare-economics.json | 24 +++++++++++++++++++ ...ehensive-semaglutide-medicare-economics.md | 17 ++++++++++++- 6 files changed, 64 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 8958d7930..9afa4e8f9 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -53,6 +53,12 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated. + +### Additional Evidence (challenge) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16* + +Medicare-specific modeling shows net savings of $715M over 10 years when multi-indication benefits are included, with T2D savings ($892M) exceeding obesity costs ($205M). The distinction is critical: system-level inflation can coexist with payer-level savings when the entity bearing drug costs also captures downstream disease prevention savings. This suggests the 'inflationary through 2035' claim needs scope qualification between fee-for-service system economics and risk-bearing payer economics. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 764c971a2..9e0381c49 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -54,6 +54,12 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0 Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk. + +### Additional Evidence (confirm) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16* + +Quantified multi-organ savings in Medicare population: $14,431/subject from avoided T2D, $2,074/subject from avoided CKD, $1,512/subject from avoided CV events. Per 100,000 subjects: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided. The compounding effect is measurable and substantial enough to offset $47,353 average lifetime treatment costs. + --- Relevant Notes: diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 278f2b9b6..cca804633 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -40,6 +40,12 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings. + +### Additional Evidence (extend) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16* + +Medicare-specific modeling quantifies CKD savings at $2,074 per subject treated, which is smaller than T2D savings ($14,431/subject) but still material. The 10-year window may underestimate CKD value since dialysis costs accumulate over longer timeframes. + --- Relevant Notes: diff --git a/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md b/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md index 480ec5924..ef0715199 100644 --- a/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md +++ b/domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md @@ -47,6 +47,12 @@ PACE represents the 100% risk endpoint—full capitation for all medical, social The BALANCE Model moves payment toward genuine risk by adjusting capitated rates for obesity and increasing government reinsurance for participating MA plans. This creates a direct financial incentive mechanism where plans profit from preventing obesity-related complications rather than just managing them. The model explicitly tests whether combining medication access with lifestyle supports under risk-bearing arrangements can shift the payment boundary. + +### Additional Evidence (extend) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16* + +The Medicare semaglutide analysis demonstrates why full-risk arrangements change prevention economics: when the same entity pays for drugs AND captures downstream savings, comprehensive GLP-1 access becomes cost-saving ($715M over 10 years). This is the mechanism by which risk-bearing payment models enable prevention investments that fee-for-service cannot justify. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json b/inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json new file mode 100644 index 000000000..4a11d8594 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json @@ -0,0 +1,24 @@ +{ + "rejected_claims": [ + { + "filename": "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-bears-both-costs-and-downstream-savings.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 1, + "rejected": 1, + "fixes_applied": [ + "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-bears-both-costs-and-downstream-savings.md:set_created:2026-03-16" + ], + "rejections": [ + "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-bears-both-costs-and-downstream-savings.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md b/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md index e5b44f11a..1205b5f46 100644 --- a/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md +++ b/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md @@ -7,9 +7,13 @@ date: 2025-06-01 domain: health secondary_domains: [internet-finance] format: paper -status: unprocessed +status: enrichment priority: high tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -39,3 +43,14 @@ Key findings: PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction. + + +## Key Facts +- Medicare net savings projection: $715M over 10 years (range $412M-$1.04B) +- 38,950 cardiovascular events avoided over 10 years +- 6,180 deaths avoided (CV + CKD/MASH) +- T2D-related savings: ~$892M +- Obesity-related costs: ~$205M +- MASH-related savings: ~$28M +- Average per-subject lifetime treatment costs: $47,353 +- Per-subject savings breakdown: T2D $14,431, CKD $2,074, CV events $1,512